Tumor Microenvironment and Microvascular Density in Follicular Lymphoma.
NHL
angiogenesis
follicular lymphoma
tumor microenvironment
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Feb 2022
25 Feb 2022
Historique:
received:
14
02
2022
revised:
22
02
2022
accepted:
23
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Follicular lymphoma (FL) is a slowly progressive disease and constitutes the second most common non-Hodgkin lymphoma. Biological factors, such as the tumor microenvironment and the host response, are determinants in the outcome of FL but the experimental data about microenvironment and tumor cells in FL are variable and contradictory. In this morphometric study, we analyzed by immunohistochemistry the cellular components of the tumor microenvironment and correlated these data with the microvascular vascular density in three different grades of FL lymph node biopsies, comparing the results to healthy lymph node controls. The results indicated a significant increase in the number of CD68
Identifiants
pubmed: 35268349
pii: jcm11051257
doi: 10.3390/jcm11051257
pmc: PMC8911525
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2008 Jan 20;26(3):440-6
pubmed: 18086798
Br J Cancer. 1998 Jun;77(11):1900-6
pubmed: 9667666
Rinsho Ketsueki. 2021;62(8):1070-1076
pubmed: 34497193
J Hematol Oncol. 2021 Jun 5;14(1):88
pubmed: 34090506
Am J Hematol. 2015 Dec;90(12):1171-8
pubmed: 26769125
Rom J Morphol Embryol. 2011;52(3 Suppl):1091-6
pubmed: 22119830
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
Leuk Lymphoma. 2018 Nov;59(11):2749-2751
pubmed: 29569979
Blood. 2008 May 1;111(9):4764-70
pubmed: 18174380
J Clin Med. 2020 Jul 28;9(8):
pubmed: 32731512
Cancer Med. 2019 Aug;8(10):4709-4721
pubmed: 31222971
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Blood. 2013 Feb 21;121(8):1367-76
pubmed: 23297127
Leuk Lymphoma. 2007 Mar;48(3):584-95
pubmed: 17454603
J Clin Oncol. 2013 Jul 20;31(21):2654-61
pubmed: 23775959
Cancer Cell. 2009 Aug 4;16(2):91-102
pubmed: 19647220
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Hum Pathol. 2016 Aug;54:17-24
pubmed: 27045512
Cell Prolif. 2019 May;52(3):e12571
pubmed: 30714229
J Immunol. 2001 Mar 15;166(6):3890-9
pubmed: 11238633
Haematologica. 2020 Jun;105(6):1593-1603
pubmed: 31537685
Semin Oncol. 1993 Oct;20(5 Suppl 5):75-88
pubmed: 8211209
Biochim Biophys Acta. 2009 Aug;1796(1):19-26
pubmed: 19233249
Br J Haematol. 2019 May;185(4):713-717
pubmed: 30793297
N Engl J Med. 2004 Nov 18;351(21):2159-69
pubmed: 15548776
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97
pubmed: 17255259
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Leuk Lymphoma. 2020 Mar;61(3):567-574
pubmed: 31623480
J Clin Oncol. 2006 Dec 1;24(34):5350-7
pubmed: 17135637
Blood. 2014 Mar 20;123(12):1836-49
pubmed: 24452203
Blood Cancer J. 2021 Jul 15;11(7):130
pubmed: 34267181
Blood Cancer J. 2012 Jan;2(1):e52
pubmed: 22829236
F1000Prime Rep. 2015 Jan 05;7:09
pubmed: 25705392
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Ann Oncol. 2009 Mar;20(3):413-24
pubmed: 19088170
Oncoimmunology. 2015 Apr 2;4(8):e1026530
pubmed: 26405585
Immunol Rev. 2019 Mar;288(1):214-239
pubmed: 30874354
Haematologica. 2009 Jan;94(1):70-7
pubmed: 19059937
Cancer Cell. 2016 Jul 11;30(1):18-25
pubmed: 27411586
Am J Hematol. 2018 Feb;93(2):296-305
pubmed: 29314206
J Immunol. 1990 Apr 1;144(7):2550-7
pubmed: 1969451
Blood. 2011 Nov 17;118(20):5371-9
pubmed: 21856865
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Immunol Rev. 2021 Jul;302(1):273-285
pubmed: 34060097
J Clin Oncol. 2006 Nov 1;24(31):5052-9
pubmed: 17033038
Leuk Lymphoma. 2003 Mar;44(3):517-21
pubmed: 12688324
J Hematol Oncol. 2021 Feb 16;14(1):27
pubmed: 33593403
Histopathology. 2001 Aug;39(2):150-5
pubmed: 11493331
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562694
Clin Cancer Res. 2015 Aug 1;21(15):3428-35
pubmed: 25869385
Clin Cancer Res. 2009 Oct 15;15(20):6446-53
pubmed: 19808874
Blood Adv. 2017 Jul 07;1(16):1263-1273
pubmed: 29296768
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Lancet Oncol. 2014 Jan;15(1):69-77
pubmed: 24332512
Front Oncol. 2018 Sep 10;8:351
pubmed: 30250823
Trends Immunol. 2019 Apr;40(4):310-327
pubmed: 30890304
Blood. 2009 Jul 23;114(4):826-34
pubmed: 19471018
Cancer Immunol Immunother. 2021 Dec;70(12):3573-3585
pubmed: 33929583
Blood Cancer J. 2020 Jul 17;10(7):74
pubmed: 32678074
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Oncoimmunology. 2015 Feb 3;4(5):e1002728
pubmed: 26155390
Cancer Sci. 2018 Jan;109(1):43-53
pubmed: 29034543
Curr Pharm Biotechnol. 2000 Jul;1(1):1-9
pubmed: 11467356
Front Oncol. 2018 May 08;8:147
pubmed: 29868471
Diagn Pathol. 2020 Apr 3;15(1):31
pubmed: 32245492
Haematologica. 2010 Dec;95(12):2157-60
pubmed: 20713461
Leuk Res. 2014 Nov;38(11):1374-7
pubmed: 25293515
Blood. 2008 May 1;111(9):4664-7
pubmed: 18309035
Appl Immunohistochem Mol Morphol. 2012 Jan;20(1):41-6
pubmed: 21768878
Br J Haematol. 2020 Oct;191(2):243-252
pubmed: 32383789
Anticancer Res. 2021 Mar;41(3):1291-1297
pubmed: 33788720
Blood. 2012 Sep 6;120(10):2042-54
pubmed: 22837530